Study of Novel 4,5,6,7-Tetrahydro-7H-Pyrazolo[3,4-c]Pyridine-7-Ketone Derivatives as Orally Effective ATX Allosteric Inhibitors for Treating Pulmonary Fibrosis
Chapter One: Biological Background and Therapeutic Potential of the ATX Target
Autotaxin (ATX), a member of the ecto-nucleotide triphosphate diphosphohydrolase family (ENPP2), is currently known to be a key rate-limiting enzyme in the generation of lysophosphatidic acid (LPA) in the circulatory system. This enzyme plays a central regulatory role in various physiological and pathological processes by catalyzing the hydrolysis reaction of lysophosphatidylcholine (LPC). From a molecular mechanism perspective, the ATX-LPA signaling axis mediates downstream signal transduction through G protein-coupled receptors and is widely involved in fundamental life activities such as cell proliferation, migration, and survival. Its abnormal activation is closely related to major diseases like fibrotic diseases and tumorigenesis.
During embryonic development stages, experiments with ATX gene knockout have confirmed that this pathway plays an irreplaceable role in angiogenesis and neural crest development. In adult individuals, pathological studies show significant overexpression of ATX and elevated LPA levels in lung tissues from patients with pulmonary fibrosis. More critically, mice with ATX gene knockout exhibit significant resistance to bleomycin-induced pulmonary fibrosis; this finding provides direct evidence for targeting ATX as an antifibrotic treatment strategy. From a drug development perspective, ATX inhibitors possess unique advantages: first, their active regulation window is wide enough that potent inhibitors can reduce plasma LPA levels by more than 95%; second, ATX functions redundantly under normal physiological conditions so long-term inhibition does not cause obvious toxic side effects. These characteristics make ATX an extremely valuable target for antifibrotic drug development.
Chapter Two: Discovery and Structural Optimization of Lead Compounds
Based on crystal structure analysis of ATX (PDB ID: 5KXA), its active site exhibits typical ternary structural features including hydrophobic pockets, hydrophobic tunnels, and catalytic sites. Using known inhibitor PAT-409 as a starting point through systematic structure–activity relationship studies, it was found that its indole scaffold forms critical π–π stacking interactions with TRP255 residues while carboxyl groups form hydrogen bond networks with VAL278 residues. However,the lead compound has notable defects: sulfide groups result in high clogP values (>5), severely affecting drug-like properties. Through scaffold hopping strategies,we replaced the indole core with a 4,5,6,-tetrahydro-7H-pyrazolo[3,c]pyridine-7-ketone framework which significantly improved molecular polarity.In our first round optimization we introduced aromatic “tail” groups(phenyl/benzyl) at nitrogen atoms on lactam rings.The resulting compounds 10–14 exhibited nanomolar level inhibitory activity(IC50=26.5–38.5 nM)while optimizing clog P values down to around 2.5.Molecular docking showed that new bicyclic scaffolds maintained π−π interactions with TRP255 while their benzoate fragments formed stable salt bridges with LYS249—this being foundational for high activity structures.Further structure–activity relationship studies revealed that N-substituent lengths on pyrazole rings had significant impacts on activity.Replacing propyl group substituents by methoxymethyl led representative compounds31and35to IC50values reaching2 .8 nMand0 .7 nM respectively—an increase two orders higher than initial lead compounds.Detailed structural analyses indicated31’s benzyl tail forming bent conformations connected via methylene perfectly fit into hydrophobic pocket stereochemistry; meanwhile35’s phenyl connection though having superior activity posed spatial repulsion issues.This subtle structural difference provided important directions for subsequent optimizations.
Chapter Three: Pharmacokinetic Characteristics Of Candidate Compounds
Using QikProp software predictions revealed compounds31and35exhibited excellent pharmacokinetic parameters: w solubility(QPlogS -7 .205to -6 .500) and lipophilicity(QPlog P4 .342to4 .500 )both fell within ideal ranges,predicting oral absorption rates at54%.Notably,both demonstrated outstanding safety profiles regarding CNS permeability(-2 )&hERG channel inhibition(log hERG<−5)#stars value recorded zero(reference compoundPAT −409was four). laboratory validations illustrated35showcased remarkable metabolic stability within rat liver microsomes(t1/2108min ,CLint12μL/min/mg ).In vivo pharmacokinetics investigations suggested this compound achieved69%oral bioavailability manifesting moderate clearance(CL=31mL/min/kg)&suitable distribution volumes(Vss57.L/kg).These data indicate potential viability towards becoming orally administered drugs exhibiting ideal pharmacological traits.
Chapter Four: In Vitro Pharmacodynamics Evaluation
in MRC -five human lung fibroblast models ,compounds31&35demonstrated no cytotoxicity at80 μM concentrations confirming good safety profiles.Evaluating key pathological aspects surrounding pulmonary fibrosis indicated TGFβ1 induced cellular migration assays showed treating24hours using10μg/mLof35dropped wound healing rates from83%downward toward26%, outperforming positive control PAT −409(42%). molecular-level assessments discovered how34significantly inhibited expression markers linked directly back towards fibrogenesis α-SMA mRNA decreased twofold,FN mRNA threefold indicating multi-target suppression mechanisms possibly engaging TGFβ /Smad signaling pathways notably36displayedIC50>30μMin regard toward hERG channels far exceeding therapeutic concentration thresholds showcasing exceptional cardiac safety profiles herein! display experimental verification shows how these findings validate substantial efficacy against overall animal models proving clear anti-fibrotic benefits observed across multiple dimensions ! after conducting histopathological examinations revealing enhanced alveolar integrity reduction inflammation infiltration collagen deposition alongside Masson staining demonstrating reduced areas fibroses surpassing fifty percent along immunofluorescence detection showingα-SMA positivity dropped39 %downwards below five percent!All results collectively affirm robust performance potentials displayed throughout respective preclinical settings! n ###Chapter Five : Conclusion & Outlook The study successfully developed novel derivatives namely ; specifically targeting Autotaxin employing strategic approaches involving optimized structures leading up promising candidates capable achieving noteworthy inhibitory activities accompanied favorable pharmacologic properties evident clinical implications emerging postulated future research will emphasize expanding evaluations focused upon ensuring comprehensive preclinical safety assessment exploring combination therapies integrating other existing agents whilst delving deeper understanding underlying mechanisms regulatingTGF β / Smad pathways based off current insights suggestive compound #has strong prospects emerging breakthrough candidate tackling challenging ailments offering fresh avenues treatments applicable severe cases associated respiratory disorders.